TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Tolerability measured by self-report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and Specificity of the Novel Protein Indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with positive anti-αIIbβ3 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fetal/neonatal death
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants with no vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prospective memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Calcium phosphate supersaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Location of injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laterality of injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanism of injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Perceived Age mean change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of morphometric vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Children's Self Report of Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: No device- or procedure-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: No major amputation of the treated limb
Endpoint domain: Mortality/survival
Primary endpoint: Revascularization rate of the clinically indicated target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Completeness of reporting lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ecchymosis of the arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: RSV-associated LRTD hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Change in cytokines level in circulating blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cytokines level in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Public Speaking Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Working Alliance Inventory-Short Revised (WAI-SR), Total Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in salivary cotinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in secondhand smoke exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synaptic density changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specific Levels of Functioning Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Baseline cognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Baseline peripheral blood neuropathology biomarkers level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline brain structural MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Baseline brain functional MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Baseline simultaneous EEG-fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of time glucose levels in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional outcome of the hip revision surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in patient function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile TL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile TDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile C/D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in dry eye symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uremic toxins reduction ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical efficacy of FMT versus sham transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-second Chair Stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic efficacy Evaluation
Endpoint domain: Physiological/clinical
Primary endpoint: Transgender Congruence Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gender Affirming Hormone Treatment Physical Symptoms Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transgender individual Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Success of IANB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IHS4 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of DT versus TF ablation catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of DT versus TF ablation catheter
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic equivalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vascular uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: SCERTS Assessment Process
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Primary outcome measurement
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Health Status Questionnaire (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Numeric Scale (VNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of Sexual Function (IFSF)
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Study participant retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Study material completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pressure Ulcer prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 10-meter walk test at self-selected speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-meter walk test at fast speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BERG Balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients preventing the use of health resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: GABA receptor binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain threshold assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anemia prevalence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of ICTP in GCF and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of CTX in GCF and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Audiometric Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Type of Reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic mitochondrial TCA cycle fluxes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Restoration condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in score of the 3F Test Dysarthric Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nature, frequency and severity of Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month RFS rate
Endpoint domain: Mortality/survival
Primary endpoint: 12-month PFS rate
Endpoint domain: Mortality/survival
Primary endpoint: Vulvovaginal atrophic symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnea perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum observed drug concentration (Cmax) of AZD4604
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum observed concentration (tmax) of AZD4604
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under concentration-time curve in the dosing interval (AUCtau) of AZD4604
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in buprenorphine treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Urinary biomarker evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fecal biomarker evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood biomarker evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Limb Motion Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Temporomandibular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Of Pain intensity at post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Disability associated with low back pain at post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score for Patellofemoral Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint pain intensity in the most affected joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute gout recurrence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Laboratory Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events and Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Eastern Cooperative Oncology Group (ECOG) Performance scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Students' Substance Use Risk Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Self-Control Levels of Students at Risk of Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total consumption of fentanyl in 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Units of Experience (SUE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in days with headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients free from peri-implantitis
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical evaluation of oral mucosa disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evaluation of perioral mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evaluation of surface and texture of oral mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupil examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global end-expiratory lung impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Father Support Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ordinal scale of WHO categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with abnormal blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with Syncopes/Presyncopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2-hour postprandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived Stress Scale-10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life reduction over 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Additional debridement following IFA use
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of nodule localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect size of intervention (Cohen's D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate to the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy of endoscopic assessment for risk of SMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASDAS CRP major improvement criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in urine albumin creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in salivary aldosterone levels in response to the stress task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in plasma aldosterone levels in response to the stress task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in plasma angiotensin II levels in response to the stress task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in plasma renin levels in response to the stress task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Optimal Complementary Feeding Practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Plasma concentrations of Glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of employees without varicella-specific antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in 17-item Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in anxiosomatic cluster symptoms derived 17-item Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline General movements at 40 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from 40 weeks Denver II Developmental Screening Test at 4 months of corrected age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean difference in cycloplegic SERE change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in axial length change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with ribociclib and everolimus-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Disability-Adjusted Life Years (DALY)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of participants with substantial reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone Mineral Density of the total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density of the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight mean change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist circumference mean change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting blood glucose mean change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin A1c mean change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oral glucose tolerance test mean change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with partial sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in subjective cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maternal, fetal, and neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: Neonatal intensive care unit (NICU) admissions
Endpoint domain: Adverse events/effects
Primary endpoint: Central SBP difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in maximal orthogonal diameter of the infrarenal aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence rate of AMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-related adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-Training Scores on CIP Scale Sensitive Responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-Training Scores on CIP Scale Respect for Children's Autonomy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Post-Training Scores on CIP Scale Structuring and Limit Setting
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Post-Training Scores on CIP Scale Verbal Communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Post-Training Scores on CIP Scale Developmental Stimulation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Post-Training Scores on CIP Scale Fostering Positive Peer Interactions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Determinants of Health (SDOH) Assessment Completion
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Parental depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of non-traumatic pathologies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of GLPG3667
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of GLPG3667
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Grade II-IV Acute GVHD by Day +100
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of uncontrolled patients with treatment modification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients alive and without progression at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Arterial elastance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate variability measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful execution of differential diagnosis protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Composite response rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient neurotoxicity questionnaire (PNQ)
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue aggregation of Hyaluronic Acid fillers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of Hyaluronic Acid fillers using ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes